BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murphy MJ, Gruenstein D, Wang A, Peterson D, Levitt J, King B, Damsky W. Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis. JAMA Dermatol 2021. [PMID: 34757416 DOI: 10.1001/jamadermatol.2021.4084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Takeuchi S, Fukuda K, Tanaka R, Funakoshi T, Takahashi H, Amagai M, Tanikawa A. Successful management of tumor necrosis factor‐α inhibitor‐induced erythema multiforme by switching to a Janus kinase inhibitor in a patient with rheumatoid arthritis and ulcerative colitis. The Journal of Dermatology 2022. [DOI: 10.1111/1346-8138.16643] [Reference Citation Analysis]
2 McCarthy MW. Treatment of severe COVID-19: an evolving paradigm. Expert Opin Pharmacother 2022. [PMID: 36271630 DOI: 10.1080/14656566.2022.2140041] [Reference Citation Analysis]
3 Weill A, Descamps V, Chasset F, Mahévas T, Bourgault-Villada I, Wolkenstein P, Chollet-Martin S, Ingen-Housz-Oro S, Grootenboer-Mignot S. Erythema multiforme associated with anti-plakin antibodies: a multicentric retrospective case series. J Eur Acad Dermatol Venereol 2022. [PMID: 35607912 DOI: 10.1111/jdv.18259] [Reference Citation Analysis]
4 Dominguez AR, Lopez SN. Novel Treatments for Chronic Erythema Multiforme Inform Translational Science and Disease Pathogenesis. JAMA Dermatol 2021;157:1411-3. [PMID: 34757395 DOI: 10.1001/jamadermatol.2021.4082] [Reference Citation Analysis]